Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.

ABSTRACT:

Background

Patterns of treatment failure and subsequent treatment in non-small cell lung cancer (NSCLC) patients treated with osimertinib are scarcely known. We analyzed the disease progression during osimertinib treatment to identify potential treatment strategies.

Methods

We identified advanced NSCLC patients who commenced osimertinib treatment after progression on previous epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) from June 2014 to November 2018 from electronic records. Patients' tumor characteristics, efficacy outcomes, affected organs from radiology studies, and treatment modalities before and after osimertinib were analyzed.

Results

Eighty-four patients were included. At osimertinib initiation, bone (50.0%) and brain (41.9%) were th

SUBMITTER: Kim HS 

PROVIDER: S-EPMC10278531 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature